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ABSTRACT
Objectives Treatment options for preventing vaso- 
occlusive crises (VOC) among patients with sickle cell 
disease (SCD) are limited, especially if hydroxyurea 
treatment has failed or is contraindicated. A systematic 
literature review (SLR) and network meta- analysis (NMA) 
were conducted to evaluate the efficacy and safety of 
crizanlizumab for older adolescent and adult (≥16 years 
old) SCD patients.
Methods The SLR included randomised controlled trials 
(RCTs) and uncontrolled studies. Bayesian NMA of VOC, 
all- cause hospitalisation days and adverse events were 
conducted.
Results The SLR identified 51 studies and 9 RCTs on 14 
treatments that met the NMA inclusion criteria. The NMA 
found that crizanlizumab 5.0 mg/kg was associated with 
a reduction in VOC (HR 0.55, 95% credible interval (0.43, 
0.69); Bayesian probability of superiority >0.99), all- cause 
hospitalisation days (0.58 (0.50, 0.68); >0.99) and no 
evidence of difference on adverse events (0.91 (0.59, 1.43) 
0.66) or serious adverse events (0.93 (0.47, 1.87); 0.59) 
compared with placebo. The HR for reduction in VOC for 
crizanlizumab relative to L- glutamine was (0.67 (0.50, 
0.88); >0.99). These results were sensitive to assumptions 
regarding whether patient age is an effect modifier.
Conclusions This NMA provides preliminary evidence 
comparing the efficacy of crizanlizumab with other 
treatments for VOC prevention.
INTRODUCTION
Sickle cell disease (SCD) affects approx-
imately 100 000 people in the USA.1 The 
disease is caused by an autosomal- recessive 
single gene defect in the beta chain of haemo-
globin, which results in sickle cell haemo-
globin. Sickled cells break down prematurely, 
and are associated with varying degrees of 
anaemia. Interactions of red blood cells, white 
blood cells, platelets and endothelial cells are 
an important contributor to the pathophys-
iology of SCD.2–7 For instance, endothelial 
cells lining the vasculature are activated and 
have increased expression of adhesion mole-
cules in SCD patients; this plays a central role 
in the development of vaso- occlusion.3 8 9 
Ultimately, obstruction of small blood capil-
laries causes painful crises, damage to major 
organs and increased vulnerability to severe 
infections. Over the past several decades, 
life expectancy has improved, however, the 
disease continues to be associated with early 
mortality and high morbidity.10 The aim of 
treatment is to aid disease and chronic pain 
management, reduce severity and/or prevent 
complications and manage acute pain during 
crises.11
There is no widely available cure for SCD 
and few effective treatments. Hydroxyurea 
and L- glutamine (Endari), the only two Food 
and Drug Administration (FDA)- approved 
drugs for SCD, are indicated for the preven-
tion of vaso- occlusive crises (VOC).12 In a 
2- year paediatric study, per patient health-
care costs for children on hydroxyurea were 
$9450, compared with $13 716 for those who 
did not receive this treatment.13 Despite the 
National Heart, Lung and Blood Institute’s 
recommendations, hydroxyurea is not regu-
larly prescribed and adherence to the therapy 
Strengths and limitations of this study
 ► This systematic literature review was comprehen-
sive in terms of outcomes and interventions and was 
focused on the target population of crizanlizumab.
 ► To include a diverse range of outcome summaries, a 
shared parameter Bayesian network meta- analysis 
was employed, as recommended by National 
Institute for Health and Care Excellence.
 ► Risk of bias was assessed using the best practice 
Cochrane collaboration tool.
 ► It was not possible to adjust for differences in sta-
tistical analysis across randomised controlled trials.
 ► The strength of comparisons on outcomes other 
than vaso- occlusive crises (VOC) was weak, and 
VOC may not be the key outcome for patients.
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is poor.14 Further, there are no current clinical guide-
lines outlining when to integrate L- glutamine into care. 
Regular blood transfusions can also be used as a preven-
tive measure, but they may also lead to abnormally high 
levels of iron in the blood, which can cause long- term 
organ damage and reactions due to a mismatch between 
the donors and recipients.14 Voxelotor has shown an 
ability to increase haemoglobin levels in patients with 
SCD15 and in November 2019 was FDA- approved.16
Crizanlizumab is a new, FDA- approved17 drug for the 
prevention of VOC. A phase II multicentre, randomised, 
placebo- controlled, double- blind, 12- month study was 
completed to evaluate crizanlizumab 5.0 mg/kg and 
2.5 mg/kg versus placebo.18 This study found that the 
median rate of crises per year was 1.63 with crizanlizumab 
5.0 mg/kg versus 2.98 mg/kg with placebo (indicating a 
45.3% lower rate with high- dose crizanlizumab 5.0 mg/
kg, p=0.01). The median time to the first VOC was also 
significantly longer with high- dose crizanlizumab 5.0 mg/
kg than with placebo (4.07 vs 1.38 months, p=0.001), as 
was the median time to the second VOC (10.32 vs 5.09 
months, p=0.02). In addition, the median rate of uncom-
plicated crises per year was 1.08 with crizanlizumab 
5.0 mg/kg, as compared with 2.91 with placebo (indi-
cating a 62.9% lower rate with crizanlizumab 5.0 mg/kg, 
p=0.02).
The comparative efficacy and safety of crizanlizumab has 
been evaluated against placebo, however, head- to- head 
randomised controlled trial (RCT) evidence is lacking 
for comparisons to treatments of interest. Network meta- 
analysis (NMA) is a statistical method that allows for the 
simultaneous evaluation of all treatments within a thera-
peutic area and allows for indirect comparisons between 
treatments where head- to- head evidence may not be avail-
able. Specifically, NMA can be used to combine direct and 
indirect evidence regarding any interventions that form a 
network of RCTs where each trial has at least one inter-
vention (active or placebo) in common with another trial 
and all RCTs are sufficiently similar.19 20 To minimise risk 
of bias, RCTs should be identified through a comprehen-
sive systematic literature review (SLR) using pre- defined 
criteria.21
This study conducts an SLR and NMA to assess the 
comparative efficacy and safety of crizanlizumab against 
relevant competing interventions for older adolescent 
and adult (≥16 years old) patients with SCD.
METHODS
Systematic literature reviews
The SLR protocol was finalised on 25 June 2018 and the 
SLR was conducted according to Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses 
(PRISMA) guidelines.22 A PRISMA NMA checklist can 
be found in online supplemental appendix A. The SLR 
approach updated and expanded an earlier published 
SLR by Sins et al23 by including non- controlled studies and 
included additional interventions. Inclusion and exclu-
sion criteria for studies are summarised in table 1. Rele-
vant studies were identified by searching the following 
databases: Cochrane Central Register of Controlled Trials 
(CENTRAL); Medical Literature Analysis and Retrieval 
Table 1 Study selection criteria to identify trials for the systematic literature review
Criteria Description
Population Studies included adult patients with sickle cell disease (SCD)
Interventions  ► Crizanlizumab
 ► L- glutamine
 ► Voxelotor (GBT440)
 ► Red blood cell transfusions
 ► Other types of transfusions
 ► Any pharmacological interventions for preventing crisis, pain and/or vaso- occlusive crisis 
(VOC)
Comparators  ►  Placebo or best supportive care
 ►  Any of the listed interventions of interest
 ►  Any treatment that facilitates an anchored indirect comparison
Outcomes Primary outcome:
 ►  Pain, crisis and VOC (frequency, intensity and duration in one event)
Secondary outcomes:
 ►  Hospital admission, including emergency department and nurse visits
 ►  SCD complications, including acute chest syndromes
 ►  Analgesic use
 ►  Adverse events*
Study design  ► Randomised controlled trials (RCTs)
 ► Single- arm trials when RCTs are not available for the interventions of interest
Language English
*In addition to efficacy outcomes, adverse events are of interest for the review, but will not be used as study selection criteria.
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System Online (MEDLINE) and Excerpta Medica data-
base (Embase). We also searched a trial registry,  Clinical-
Trials. gov. The search strategies were derived from Sins et 
al23 and can be found in online supplemental appendix 
B along with the complete search protocols in online 
supplemental appendices C and D. As blood transfusion 
was not included by Sins et al,23 we conducted a separate 
search for blood transfusion from inception of databases 
to 30 August 2018. For non- transfusion studies, the search 
date was from 1 January 2017 to 21 June 2018 to bridge 
the findings of Sins et al.23
Results of searches were managed using Endnote and 
a Microsoft Excel spreadsheet. Two reviewers screened 
and selected records independently against inclusion and 
exclusion criteria using titles and abstracts. Full texts of 
potential eligible records were retrieved and screened to 
assess the eligibility for data extraction. Disagreements 
were resolved by discussion and consensus. Following 
reconciliation between the two investigators, a third 
investigator was included to reach consensus for any 
remaining discrepancies. The Cochrane collaboration’s 
risk of bias tool was used to assess risk of bias in included 
RCTs.24 The Newcastle- Ottawa Scale was used to assess the 
quality of non- controlled studies.25
The primary outcome of this review was sickle cell 
pain crisis, also known as a VOC leading to a healthcare 
visit. A variety of definitions for VOC was observed in the 
included studies. We consulted several medical experts 
and chose the definition of VOC used in the pivotal 
phase II RCT of crizanlizumab.18 In this trial, a VOC was 
defined as an acute episode of pain, with no medically 
determined cause other than a vaso- occlusive event that 
resulted in a medical facility visit and treatment with oral 
or parenteral opioids or with a parenteral non- steroidal 
anti- inflammatory drug. In addition to outcomes specifi-
cally named as VOC, the outcomes of pain crisis and SCD 
crisis were extracted and included with the VOC set if 
found to use a comparable definition.
Other outcomes identified as of interest and/or 
extracted included pain- related outcomes, acute chest 
syndrome, all- cause hospitalisations, transfusions, anal-
gesic use, death, adverse events and serious adverse 
events. In addition to study and intervention characteris-
tics, the patient characteristics were extracted to qualita-
tively assess comparability of different study populations.
Network meta-analysis
This paper adopts the Bayesian statistical framework to 
conduct the NMA. This is different to the frequentist 
framework as the data, represented as a likelihood, are 
used to update a prior distribution on uncertain param-
eters to provide a posterior distribution.26 Bayesian NMA 
is conducted using Markov chain Monte Carlo (MCMC) 
estimation which is a technique to sample from the 
posterior distribution of a specified likelihood and prior. 
The Bayesian framework is recommended by National 
Institute for Health and Care Excellence (NICE) and 
published textbooks for NMA due to its flexibility and in 
this study it allows the synthesis of different data types, 
which would be difficult in the frequentist setting.27 28 
The key outputs of a Bayesian analysis are 95% credible 
intervals (CrI) and Bayesian probabilities. The 95% CrI is 
the 95th percentile of the MCMC samples from the poste-
rior distribution and represents a region where there 
is 95% probability of containing the true value of some 
parameter, for example, an HR. The Bayesian probability 
for a parameter is the proportion of the MCMC distribu-
tion that lies above or below a certain threshold; in this 
analysis, the interest lies in Bayeisan probabilities of supe-
riority which are the probability that the HRs are >1.
Quantitative synthesis through this Bayesian NMA 
approach was planned for reported or derived time- to- 
event outcomes of VOC, all- cause hospitalisation days, 
adverse events and serious adverse events, in line with 
those reported by the phase II RCT on crizanlizumab.18 
International Society for Pharmacoeconomics and 
Outcomes Research, Society for Medical Decision (MDM) 
and UK NICE guidelines were followed in design of the 
NMA model.27 29–31 As the pivotal study on crizanlizumab 
was conducted within an older adolescent and adult (≥16 
years old) population, the NMA was conducted only on 
studies that included patients ≥16 years old with SCD. 
While the pivotal study for L- glutamine (Niihara et al) 
included patients aged <16 years old, a decision was made 
to include the study to enable a comparison with crizanli-
zumab. The primary comparison examines the outcomes 
in the whole population. A sensitivity analysis was subse-
quently run using the results with Endari in a subgroup 
of patients aged >18 years old (reported in Niihara et 
al). Evidence networks were generated with nodes corre-
sponding to treatments and edges connecting nodes if at 
least one RCT comparing corresponding treatments was 
identified.32 An extended network including RCTs with 
a mixture of child, adolescent and adult populations was 
investigated for additional direct or indirect evidence on 
any comparison with crizanlizumab 5.0 mg/kg.
Following NICE guidelines, we employed a shared 
parameter model for HRs to synthesise studies 
summarising outcomes in different formats and 
accounting for differences in trial duration.27 Summa-
ries that could be included were total number of events, 
percentage of patients with events, mean numbers of 
events, mean or median rates, numbers of patients with 
at least one event and risk or HR of event. Likelihood and 
link function for each summary followed MDM and NICE 
guidelines.27 31 Total number of events are modelled with 
a Poisson likelihood and log link, numbers of patients 
with at least one event are modelled using a Binomial 
likelihood and complementary log log link, while risk and 
HRs are modelled on a log scale with a normal likelihood 
and identify link. In line with NICE recommendations, a 
Bayesian perspective with vague priors was adopted.27 31 
Sensitivity to priors was explored with details in online 
supplemental appendix B; the base case prior has an SD 
of 100 while the precise prior sensitivity has an SD of 3.16 
on log scale of baseline and treatment effects. Fixed and 
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random effect were considered with choice being made 
on basis of model fit; meta- regressions were also explored 
to assess heterogeneity due to trial duration, propor-
tion female, mean age, proportion homozygous haemo-
globin S (HbSS) genotype, proportion hydroxyurea use 
and proportion black or African- American.33 Different 
doses of the same drug were analysed independently. If a 
connected evidence network could be formed using only 
RCTs, single- arm study evidence was discarded. The refer-
ence treatment in all analyses was placebo. If feasible, 
inconsistency between direct and indirect evidence was 
planned to be tested by node- splitting and an indepen-
dent means inconsistency model.19 All analyses were 
conducted using the MCMC software of OpenBUGS 
V.3.2.3.34 Two MCMC chains with 400 000 iterations for 
burn- in and 30 000 iterations for posterior sampling were 
used. Convergence was assessed by visual inspection and 
the Gelman- Rubin statistic.34 35 Further details of the 
modelling methods are provided in online supplemental 
appendix E.
We generated HRs with 95% CrI of high- dose crizan-
lizumab 5.0 mg/kg relative to each comparator. We esti-
mated the Bayesian probability that crizanlizumab was 
superior (lower hazard of event) or inferior (higher 
hazard of event). These probabilities are the Bayesian 
equivalent of one- sided p values. In line with the recom-
mendations of the American Statistical Association, we 
did not adopt a strict threshold for interpreting these 
Bayesian probabilities,36 but instead reported the prob-
ability itself. Probabilities are interpreted to suggest 
evidence in favour of a hypothesis if it lay lower than 5% 
or above 95%, and weak evidence if the probability was 
between 5% and 10% or 90% and 95%.37
Patient and public involvement
Patients and/or the public were not involved in the 




We retrieved 3388 records from electronic databases,  Clin-
icalTrials. gov and Sins et al, 2017. After removing dupli-
cates and irrelevant records, we screened 250 full- text 
articles. Fifty one studies (67 references) were included 
to perform evidence evaluation for the NMA (figure 1). 
Full details and references for the 51 studies are included 
in online supplemental appendix B. We also identified 
14 additional ongoing clinical RCTs or completed RCTs 
without publication, which investigated effects of non- 
hydroxyurea treatments on SCD patients.38–51
Of 51 studies, duration of follow- up was reported in 41 
studies and, among RCTs in the ≥16 years old population, 
duration ranged from 30 days in Wun et al52 to 52 weeks 
in Ataga et al.18 This range represents substantial variation 
in follow- up, but the methods used for NMA model trial 
follow- up compare annualised hazards in order to adjust 
for this difference.
The proportion of female patients varied across RCTs, 
ranging from 0.44 in Glassberg et al53 to 0.60 in Sins et al,54 
so qualitatively similar proportions. Across all 51 studies, 
the proportion of females varied from 0.23 in Gupta et al55 
to 1.00 in de Abood et al,56 representing a more substan-
tial difference. In the ≥16 years old population RCTs, 
age ranged from 20.5 years in Pace et al57 to 35.5 years in 
Ataga et al.58 Across all 51 studies, the mean age ranged 
from 4.8 years in Adegoke et al59 to 48.8 years in Bridges 
et al.60 The proportion with HbSS genotype ranged from 
0.60 in Wun et al52 to 1.00 in several studies that restricted 
enrolment to patients with HbSS disease alone, including 
Ataga et al58 in the ≥16 years old population. Although 
HbSS is indicative of absolute outcomes (prognostic 
factor), there is no known evidence that it is an effect 
modifier, so the NMA remains feasible.33 Proportion of 
patients reported as black or African American ranged 
from 0.53 in NCT0248229861 to 1.00 in Styles.62 Several 
studies excluded patients with history of hydroxyurea 
usage, including Bao et al63 in the ≥16 years old popu-
lation. In the ≥16 years old population, this otherwise 
varied from 0.42 in Sins et al54 to 0.67 in Niihara et al,12 
making it somewhat comparable.
Construction of evidence networks
Of the 51 studies identified, there were 17 non- controlled 
studies that were excluded from the NMA due to lack 
of common comparators and potential bias. Of the 34 
remaining RCTs, only eight were conducted solely in older 
adolescent and adult (≥16 years old) patients.18 52–54 57 58 61 62 
As the only RCT identified on L- glutamine, Niihara et 
al12 was included in the network. This gave nine RCTs in 
the ≥16 years old population evidence networks. Five of 
these studies used a VOC definition comparable to that 
in Ataga et al12 18 57 58 62 (details in online supplemental 
appendix E). The only study that examined transfusions 
was a conference abstract by Vichinsky. As the authors did 
not specify the definition of VOC or a placebo control, 
this study was excluded from the NMA.64 Online supple-
mental appendix F shows the characteristics of included 
studies in the NMA. Analysed evidence networks are 
provided in figure 2.
In addition to crizanlizumab 5.0 mg/kg and 2.5 mg/
kg, multiple doses of other drugs were included in the 
networks. Ticagrelor was studied as both two times per 
day 45 mg (high- dose) and 10 mg (low- dose)61; N- acetyl-
cysteine (NAC) as 600 mg (low- dose), 1200 mg (mid- dose) 
and 2400 mg (high- dose)57; senicapoc with a loading dose 
of 20 mg two times per day for 4 days followed by 10 mg 
daily maintenance,62 and as a low- dose and high- dose 
formulation corresponding to single loading doses of 
100 mg and 150 mg, respectively, and maintenance 6 mg 
and 10 mg daily, respectively.58
Cochrane risk of bias assessment for the nine RCTs 
included in NMA is reported in full in online supple-
mental appendix E. Risk of bias was low in all categories 
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for three of these studies (two studying senicapoc and 
one mometasone), and was low in all except incomplete 
outcome data in Ataga et al.18 Three studies were at unclear 
risk of bias due to random sequence generation and allo-
cation concealment (studying ticagrelor, L- glutamine and 
NAC doses).12 57 61 Sins et al (studying NAC) was at low risk 
of bias for all categories except incomplete outcome data, 
on which it was at high risk of bias.54 Wun et al (studying 
prasugrel) was at unclear risk of bias on random sequence 
generation, allocation concealment and blinding but low 
risk of bias on remaining categories.52
NMA results
A fixed effects NMA approach was used for the primary 
analyses. The NMA models converged well and fit, assessed 
by comparing residual deviance to total number of data 
points, was good for all fixed effects analyses. Random 
effects analyses did not converge as only one RCT was 
available on each treatment contrast. Meta- regression to 
explore covariate effects did not reveal evidence of effect 
medication but convergence was poor for these models. 
Fit statistics and model assessment details are provided 
in online supplemental appendix E. Inconsistency could 
not be tested as there were no treatment contrasts on 
which both direct and indirect evidence were available.19
We discuss in turn the results of the NMA on VOC, 
all- cause hospitalisation days, adverse events and serious 
adverse events. Forest plots of HRs with 95% CI of crizan-
lizumab versus all comparators are provided in figure 3. 
Bayesian probabilities that crizanlizumab 5.0 mg/kg is 
superior or inferior are also provided in this figure. Pair-
wise results for all treatment comparisons are provided in 
online supplemental appendix E.
Figure 1 SCD prisma flow chart. NMA, network meta- analysis; SCD, sickle cell disease.
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We found evidence that crizanlizumab 5.0 mg/kg had 
a lower hazard of VOC than placebo L- glutamine (HR 
0.55, 95% CrI (0.43, 0.69); Bayesian probability crizan-
lizumab 5.0 mg/kg superior 0.9999), L- glutamine (0.67 
(0.51, 0.88); 0.9982) and senicapoc (0.46 (0.32, 0.67); 
>0.9999). We found only weak evidence that hazard of 
VOC was lower on crizanlizumab 5.0 mg/kg than crizanli-
zumab 2.5 mg/kg (0.81 (0.63, 1.05); 0.9452) or low- dose 
NAC (0.48 (0.18, 1.21); 0.9396). We found no evidence of 
a difference between crizanlizumab 5.0 mg/kg and mid- 
dose NAC (0.81 (0.29, 2.18); 0.6619), high- dose NAC 
(1.91 (0.57, 7.58); 0.1507), high- dose senicapoc (0.57 
(0.15, 2.17); 0.8010) or low- dose senicapoc (0.53 (0.14, 
1.95); 0.8334). Results are summarised in table 2. Cumu-
lative ranking plots (‘rankograms’) are provided in online 
supplemental appendix B for the interested reader for 
each of the outcomes of interest. These are plots of the 
cumulative probability that each treatment is ranked in 
the top 1, 2, 3 and so on treatments.
In a sensitivity analysis using a rate ratio of 0.64 with 
95% CI (0.45, 0.89) in a subgroup of patients aged >18 
years old reported on page 231 of the publication Niihara 
et al,12 we found no evidence that crizanlizumab had a 
lower hazard of VOC than L- glutamine (0.86 (0.57, 1.29); 
0.7707). Full results of this analysis are provided in online 
supplemental appendix E.
We found evidence that crizanlizumab 5.0 mg/kg had a 
lower hazard of all- cause hospitalisation days than placebo 
(0.58 (0.50, 0.68); >0.9999), and crizanlizumab 2.5 mg/
kg (0.58 (0.50, 0.68); >0.9999), but found evidence that 
hazard was higher than on low- dose NAC (2.08 (1.06, 
4.66); 0.0166). We found weak evidence that hazard of 
Figure 2 Evidence networks. Each node represents a treatment and nodes are connected by an edge if at least trial has 
compared the relevant treatments. Any two treatments can be compared if their corresponding nodes can be connected by 
a path of one or more edges. High- dose crizanlizumab=5 mg/kg 14 times over 52 weeks. Low- dose crizanlizumab=2.5 mg/
kg 14 times over 52 weeks. High- dose ticagrelor=two times per day 45 mg, low- dose ticagrelor=two times per day 10 mg; 
low- dose NAC=N- acetylcysteine 600 mg, mid- dose NAC=N- acetylcysteine 1200 mg, high- dose NAC=N- acetylcysteine 
2400 mg; senicapoc=loading dose of 20 mg two times per day for 4 days followed by 10 mg daily maintenance, low- dose 
senicapoc=single loading dose of 100 mg followed by maintenance 6 mg daily, high- dose senicapoc=single loading dose of 
150 mg followed by maintenance 10 mg daily. Five RCTs on crisis=Ataga et al, 2017 (crizanlizumab vs placebo), Niihara et al (L- 
glutamine vs placebo), Ataga et al, 2011 (senicapoc vs placebo), Ataga et al, 2008 (senicapoc low- dose, senicapoc high- dose 
vs placebo) and Pace et al (NAC low, mid and high dose vs placebo). Four RCTs on all- cause hospitalisation days=Ataga et al, 
2017 (crizanlizumab vs placebo), Niihara et al (L- glutamine vs placebo), Glassberg et al (mometasone vs placebo) and Sins et al 
(NAC vs placebo). Five RCTs on adverse events=Glassberg et al (mometasone vs placebo), Ataga et al, 2017 (crizanlizumab vs 
placebo), Ataga et al, 2011 (senicapoc vs placebo), Sins et al (NAC vs placebo) and Niihara et al (L- glutamine vs placebo). Five 
RCTs on serious adverse events=Ataga et al, 2017 (crizanlizumab vs placebo), Sins et al (NAC vs placebo), Wun et al (prasugrel 
vs placebo), NCT02482298 (TICAGRELOR vs placebo) and Niihara et al (L- glutamine vs placebo). RCTs, randomised controlled 
trials; VOC, vaso- occlusive crises.
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all- cause hospitalisation days was higher on crizanlizumab 
5.0 mg/kg than on L- glutamine (1.73 (0.82, 3.76); 0.0731) 
and no evidence of a difference with mometasone (0.89 
(0.63, 1.26); 0.7496). Note that all- cause hospitalisation 
includes admission for VOC but also for adverse events 
and non- SCD related causes.
The hazard of adverse events—both serious and 
overall—for crizanlizumab was generally similar or weakly 
better than other treatments. The exception is that there 
was weak evidence that crizanlizumab 5.0 mg/kg had 
a lower hazard than mometasone (0.51 (0.21, 1.19); 
0.9399). We found no evidence of a difference in hazard 
of adverse events between crizanlizumab 5.0 mg/kg and 
placebo (0.91 (0.59, 1.43); 0.6558), L- glutamine (1.31 
(0.62, 3.08); 0.2480), crizanlizumab 2.5 mg/kg (0.96 
(0.61, 1.48); 0.5743), low- dose NAC (0.84 (0.45, 1.60); 
0.6996) or senicapoc (0.86 (0.52, 1.44); 0.7176). Similarly, 
the hazard of serious adverse events on crizanlizumab 
5.0 mg/kg was lower than on low- dose NAC (0.20 (0.02, 
1.00); 0.9744). There was no evidence of a difference on 
adverse event rates between crizanlizumab 5.0 mg/kg and 
placebo (0.93 (0.47, 1.87); 0.5857), L- glutamine (1.24 
(0.58, 2.70); 0.2854), crizanlizumab 2.5 mg/kg (0.75 
(0.39, 1.43); 0.8134), high- dose ticagrelor (1.14 (0.27, 
4.81); 0.4247) or low- dose ticagrelor (0.81 (0.21, 3.17); 
0.6181).
Cumulative ranking plots (‘rankograms’) are provided 
in online supplemental appendix B for the interested 
reader. These are plots of the cumulative probability 
that each treatment is ranked in the top 1, 2, 3 and so 
on treatments. For crisis, qualitatively, high- dose NAC was 
most likely to have the top rank (ie, fewest events) rank 
but was closely followed by crizanlizumab 5.0 mg/kg. For 
adverse events, L- glutamine had the best (fewest events) 
rank followed crizanlizumab 5.0 mg/kg and for serious 
adverse events, L- glutamine was again best ranked while 
Figure 3 Forest plot. HR <1 suggests lower hazard of event on the crizanlizumab. Bayesian probabilities of superiority are 
proportion of MCMC samples for which crizanlizumab vs comparator HR is above (inferior) or below (superior) 1. High- dose 
crizanlizumab=5 mg/kg 14 times over 52 weeks. Low- dose crizanlizumab=2.5 mg/kg 14 times over 52 weeks. High- dose 
ticagrelor=two times per day 45 mg, low- dose ticagrelor=two times per day 10 mg; low- dose NAC=N- acetylcysteine 600 mg, 
mid- dose NAC=N- acetylcysteine 1200 mg, high- dose NAC=N- acetylcysteine 2400 mg; senicapoc=loading dose of 20 mg two 
times per day for 4 days followed by 10 mg daily maintenance, low- dose senicapoc=single loading dose of 100 mg followed by 
maintenance 6 mg daily, high- dose senicapoc=single loading dose of 150 mg followed by maintenance 10 mg daily. MCMC, 
Markov chain Monte Carlo; VOC, vaso- occlusive crises.
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crizanlizumab 5.0 mg/kg was middle ranking. For all- 
cause hospitalisation days, NAC had the best rank (fewest 
hospitalisations) and was followed by L- glutamine and 
crizanlizumab 5.0 mg/kg.
A sensitivity analysis assuming more precise priors was 
conducted and details are provided in online supple-
mental appendix B. There was little or no impact on 
results. For example, the HR of VOC for crizanlizumab 
5.0 mg/kg compared with L- glutamine was (0.67 (0.51, 
0.88); 0.9982) with precise priors and (0.67 (0.51, 
0.88); 0.9982) in the base case with vague priors. Simi-
larly, the HR of adverse event for crizanlizumab 5.0 mg/
kg compared with L- glutamine was (1.29 (0.62, 2.93); 
0.2480) with precise priors and (1.31 (0.62, 3.08); 0.2480) 
in the base case.
DISCUSSION
Previous SLRs and meta- analyses of treatments for 
SCD have demonstrated hydroxyurea to be effective in 
reducing VOC rates.65 66 However, patients receiving 
hydroxyurea therapy can continue to have crises, end- 
organ damage and a decreased life expectancy.67 Crizanli-
zumab and L- glutamine are promising treatment options 
for SCD patients not well managed on hydroxyurea, but 
no direct comparison across these treatments has been 
conducted.14 18 68 Our SLR and NMA are the first looking 
at the comparative efficacy of new treatments for older 
adolescent and adult (≥16 years old) SCD patients not 
well managed on hydroxyurea and are therefore of vital 
importance to this patient population.
Our baseline analysis found that crizanlizumab 5.0 mg/
kg reduced VOC compared with L- glutamine, placebo 
and senicapoc, and weak evidence of reduction compared 
with crizanlizumab 2.5 mg/kg and low- dose NAC. These 
results, however, were sensitive to whether the L- gluta-
mine efficacy was measured for all patients or only those 
aged >18 years.
We found that crizanlizumab 5.0 mg/kg reduced all- 
cause hospitalisation days compared with placebo and 
crizanlizumab 2.5 mg/kg. Conversely, we found evidence 
that low- dose NAC reduced hospitalisation compared 
with crizanlizumab 5.0 mg/kg, and weak evidence that 
L- glutamine reduced hospitalisation compared with 
crizanlizumab 5.0 mg/kg.
Our analysis found high- dose crizanlizumab 5.0 mg/
kg had a lower hazard of adverse events compared with 
mometasone and of serious adverse events compared 
with low- dose NAC. There was no evidence of a differ-
ence between 5 mg/kg crizanlizumab on safety with other 
treatments.
Strengths
This SLR was comprehensive in terms of outcomes and 
interventions and was focused on the target population 
of crizanlizumab, that of older adolescent and adult (≥16 
years old) SCD patients not well managed, or having 
failed previous treatment, with hydroxyurea. Our review 
followed the PRISMA guidelines and checklist.22 Risk of 
bias was assessed using the best practice Cochrane collab-
oration tool.24 To be comprehensive, we searched for both 
RCT and single- arm evidence but used only RCT evidence 






Placebo >0.9999 >0.9999 0.6558 0.5857
L- glutamine 0.9982 0.0731 0.2480 0.2854
Crizanlizumab 2.5 mg/kg 0.9452 >0.9999 0.5743 0.8134
Mometasone – 0.7496 0.9399 –
Low- dose NAC 0.9396 0.0166 0.6996 0.9744
Mid- dose NAC 0.6619 – – –
High- dose NAC 0.1507 – – –
Prasugrel – – – 0.5242
Senicapoc >0.9999 – 0.7176 –
High- dose senicapoc 0.8010 – – –
Low- dose senicapoc 0.8334 – – –
High- dose ticagrelor – – – 0.4247
Low- dose ticagrelor – – – 0.6181
High- dose ticagrelor=two times per day 45 mg, low- dose ticagrelor=two times per day 10 mg; low- dose NAC=N- acetylcysteine 600 mg, mid- 
dose NAC=N- acetylcysteine 1200 mg, high- dose NAC=N- acetylcysteine 2400 mg; senicapoc=loading dose of 20 mg two times per day for 
4 days followed by 10 mg daily maintenance, low- dose senicapoc=single loading dose of 100 mg followed by maintenance 6 mg daily, high- 
dose senicapoc=single loading dose of 150 mg followed by maintenance 10 mg daily.
*Proportion of MCMC samples for which crizanlizumab vs comparator HR is above (inferior) or below (superior) 1. Entry ‘–’ indicates 
comparator not included in outcome specific evidence network.
MCMC, Markov chain Monte Carlo; VOC, vaso- occlusive crises.
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in the NMA. Our NMA combines direct head- to- head 
RCT evidence to enable indirect comparisons of inter-
ventions (eg, crizanlizumab 5.0 mg/kg vs L- glutamine) 
that have not been compared directly; it thus goes beyond 
the published results of individual studies. Our analysis 
followed published and international guidelines on indi-
rect comparisons and NMA.27 29–31 On the outcome of 
VOC, we ensured only studies with a definition compatible 
with that of the principal crizanlizumab study were anal-
ysed.18 To include a diverse range of outcome summaries, 
such as total number of events and numbers of patients 
with at least one event, a shared parameter Bayesian NMA 
was employed, as recommended by NICE.27
Limitations
There were several limitations to this SLR and NMA. 
There was at most only one RCT on each of the treatment 
contrasts. A similar definition of VOC was used across 
RCTs but the shared parameter NMA combined RCTs 
without adjusting for differences in statistical analyses, 
such as methods for managing drop- outs, used. Differ-
ences in RCT follow- up (eg, 30 days in Wun et al52 and 52 
weeks in Ataga et al18) limit comparability of annualised 
hazard rates across treatments. The strength of evidence 
for comparisons on hospitalisation, adverse events and 
serious adverse events was weak. Furthermore, we could 
not include transfusions in the NMA as the only available 
RCT in an adult population—Vichinsky et al64—used 
an unspecified standard of care rather than a placebo 
control, did not describe the definition of VOC that was 
used, and was published only as an abstract.
Our NMA model generated results on a HR scale and 
thus used a complementary log–log link for the bino-
mial likelihood when analysing numbers of patients with 
at least one event. Although such data could have been 
modelled using a logit link, and thus generated ORs, this 
would have made it difficult to link to HR data, or total 
event data, reported by other studies. However, recent 
research has found HRs and ORs to be similar in NMA if 
the numbers of events are low, as they are in our study.69
Due to a lack of evidence, the NMA was not able to esti-
mate the relative impact of crizanlizumab treatment on 
the rate of complicated VOC or organ damage, both of 
which are important health outcomes for patients and 
physicians. The heterogeneity variance of random effects 
models was not identifiable as only one study was available 
on each contrast. Published informative priors could be 
considered.70 However, the heterogeneity variance would 
be entirely defined by this prior and its validity would 
depend on the relevance of a non- SCD clinical area as 
no NMA has been published previously in SCD. Inconsis-
tency in the network could not be assessed as there were 
no loops in the evidence networks; it was necessary to 
assume consistency to enable comparisons with crizanli-
zumab. As there was no additional indirect evidence to be 
synthesised with the direct evidence, the NMA does not 
go beyond individual study results on pairwise compari-
sons for which there is direct head- to- head evidence (eg, 
crizanlizumab 5.0 mg/kg vs placebo). In such cases, indi-
vidual study results should remain the primary source of 
comparative data.
A previous SLR in non- hydroxyurea SCD treatments 
did not conduct quantitative synthesis due to concerns 
regarding heterogeneity.23 Although we considered meta- 
regression on trial duration, proportion female, mean 
age, proportion HbSS genotype, proportion hydroxyurea 
use and proportion black or African- American, there was 
insufficient evidence as there was only one RCT on each 
treatment contrast. We were also lacking information 
on the amount of VOCs in the year preceding random-
ization/treatment start for several of the treatments 
included in the analysis, a factor known to be prognostic. 
We therefore had to assume differences in characteristics 
would not modify treatment effects, even in parameters 
expected to influence the frequency of VOCs. Although 
we conducted a sensitivity analysis using results among 
>18 year olds from Niihara et al, that study itself concluded 
that there was ‘no significant interaction between trial 
group assignment and age’.71 On the other hand, if age 
is an effect modifier, the baseline results should be inter-
preted cautiously. Future real- world evidence studies may 
be useful to explore effect modifiers and identify patient 
types that benefit most from crizanlizumab and other 
treatments.
Further, caution should be taken when interpreting 
these results in relation to switching patients from 
hydroxyurea to crizanlizumab or L- glutamine. Our anal-
ysis does not purport to compare crizanlizumab, or indeed 
L- glutamine or blood transfusions, with hydroxyurea but 
is instead focused solely on patients who are not well 
managed on hydroxyurea. Before more evidence is avail-
able, physicians should consider treatment with hydroxy-
urea before consideration of second line treatments.72
Conclusion
Our baseline analysis showed from an SLR and NMA that 
crizanlizumab reduced crises and hospital days compared 
with placebo and other treatments with an acceptable 
adverse event profile in older adolescent and adult (≥16 
years old) SCD patients when compared with other non- 
hydroxyurea treatments. The VOC results, however, were 
sensitive to assumptions regarding whether patient age is 
an effect modifier.
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